TT-P34

TT-P34 is a novel, first-in-class cyclic peptide drug developed by Teitur Trophics for the treatment of neurodegenerative diseases. The drug is designed to address three major hallmarks of neurodegeneration—mitochondrial failure, lysosomal dysfunction, and loss of pro-survival signaling—by activating the transcription factor CREB. This activation increases mitochondrial and lysosomal biogenesis as well as neurotrophic support. TT-P34 was developed from SorCS2, a receptor protein involved in protein sorting and nerve cell stress response. In preclinical studies using animal models of Parkinson’s disease, Huntington’s disease, and frontotemporal dementia, TT-P34 demonstrated robust brain-specific effects by restoring energy production in neurons, promoting clearance of toxic protein aggregates (such as those implicated in these diseases), and supporting neuronal survival through enhanced pro-survival signaling.